drugset / Trial / NCT04713982
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
Phase 2/3
Active not recruiting
30 enrolled
Vanderbilt University Medical Center
Teva Branded Pharmaceutical Products R&D, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
Examine the effects of deutetrabenazine on functional speech and gait impairment
Timeline
- Start
- 2021-11-19
- Primary completion
- 2026-06-30
- Completion
- 2026-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Deutetrabenazine | Unknown | 36 mg | Oral |
| Subject | Deutetrabenazine | Unknown | 48 mg | Oral |